Both made by Eli Lilly. Both targeting obesity and type 2 diabetes. But one is already in millions of patients' hands, and the other is producing the highest weight loss numbers ever seen in a clinical trial. A complete, honest comparison.
This is the comparison most people are searching for. The headline numbers are striking, but context matters — these come from different trials at different timepoints.
⚠ These results come from separate trials with different populations and durations. No direct head-to-head trial has been published yet. Eli Lilly is running a direct comparison trial with results expected December 2026.
Both drugs share GLP-1 and GIP receptor agonism. The difference is that retatrutide adds a third target: the glucagon receptor. Understanding what glucagon adds explains why the weight loss numbers are higher.
GLP-1 (shared): Suppresses appetite, slows gastric emptying, reduces glucagon release, improves insulin sensitivity. This is the core mechanism behind all GLP-1 class drugs.
GIP (shared): Enhances the insulin response after meals and may reduce the GI side effects associated with GLP-1 alone. GIP activation is what gave tirzepatide its tolerability advantage over semaglutide.
Glucagon (retatrutide only): This is the differentiator. Glucagon normally raises blood sugar — so adding a glucagon agonist to a diabetes drug seems counterintuitive. But in the context of GLP-1 and GIP co-activation, the blood sugar raising effect is counterbalanced. What remains is the glucagon receptor's other effects: increased energy expenditure (you burn more calories at rest), stimulation of hepatic fat oxidation (liver fat breakdown), and potentially greater fat mass loss relative to lean mass. The net result is more total weight lost, driven by both eating less and burning more simultaneously.
A network meta-analysis published in PMC comparing all available trial data found retatrutide achieved 23.77% mean weight loss versus tirzepatide's 16.79% — a meaningful difference in absolute percentage terms, though the analysis noted significant heterogeneity across trials.
| Category | Retatrutide | Mounjaro / Zepbound |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon | GLP-1 + GIP |
| Best weight loss result | 28.7% (Phase 3, 68 wks) | 22.5% (Phase 3, 72 wks) |
| Weight loss speed | 24.2% at 48 weeks | ~18–20% at comparable timepoint |
| FDA approved | No — 2027–2028 projected | Yes — 2022 (T2D), 2023 (obesity) |
| Available by prescription | No | Yes — Mounjaro & Zepbound |
| Insurance coverage | N/A (not approved) | Available for many patients |
| Long-term safety data | Limited — Phase 3 ongoing | 3+ years of real-world data |
| Liver disease (MASH) | Strong — glucagon targets liver fat directly | Effective but less targeted |
| Energy expenditure boost | Yes — glucagon increases calorie burn | Not a primary mechanism |
| Tachycardia risk | Higher — glucagon can raise HR ~5 BPM | Lower — no glucagon component |
| Dysesthesia risk | New signal — 8.8–20.9% in TRIUMPH-4 | Not reported |
| GI side effects | Broadly similar — slightly higher rates | Well-characterized, generally manageable |
| Sleep apnea indication | TRIUMPH trial ongoing | FDA approved (Zepbound, 2024) |
| Knee OA data | TRIUMPH-4: 75.8% pain reduction | Less data available |
| Cost (est.) | ~$1,000–1,500/mo (projected) | ~$1,000–1,200/mo (list price) |
Based on available trial data, yes — retatrutide produces greater weight loss than tirzepatide at comparable timepoints. The Phase 3 TRIUMPH-4 result of 28.7% at 68 weeks exceeds tirzepatide's best Phase 3 result of 22.5% at 72 weeks. A network meta-analysis confirmed retatrutide's superior efficacy. However, a direct head-to-head trial is ongoing with results expected December 2026 — that will be the definitive answer.
This is the most common question — and the answer for most people is no, don't wait. Retatrutide is 1–2 years away from approval at best. Starting tirzepatide now means real weight loss happening now. Obesity is a progressive disease with compounding health consequences. The additional weight loss from retatrutide, while real, doesn't justify a 2-year delay for most patients. If you're already on tirzepatide when retatrutide is approved, transitioning will be straightforward.
Glucagon normally raises blood sugar by triggering glycogen breakdown in the liver. But in the presence of GLP-1 and GIP receptor activation — both of which stimulate insulin and suppress glucagon's blood sugar effects — the glycemic impact is countered. What remains uncountered is glucagon's thermogenic and fat-oxidation effects. This is the key pharmacological insight behind retatrutide's design: harvest glucagon's metabolic benefits while neutralizing its diabetogenic effects.
There is no established conversion protocol yet. When retatrutide is approved, physicians will likely recommend stopping tirzepatide, allowing a brief washout period, then starting retatrutide at the lowest dose (2mg) regardless of the tirzepatide dose you were on. The titration schedule would proceed as normal. No drug interaction concerns are anticipated given both drugs work through similar pathways.
Possibly yes for glucose control specifically. Tirzepatide's dual GLP-1/GIP mechanism is highly effective at A1C reduction and is the current gold standard for type 2 diabetes pharmacotherapy. Retatrutide's glucagon component adds complexity to blood sugar management — glucagon normally raises glucose. While the net effect appears neutral-to-positive in trials, tirzepatide's glucose management profile is better understood. Physicians treating T2D primarily may prefer tirzepatide for now.
Retatrutide will almost certainly produce more weight loss than Mounjaro when the direct comparison data arrives — the trial numbers are consistently higher and the mechanism explains why. The glucagon receptor adds a dimension that tirzepatide simply doesn't have.
But Mounjaro/Zepbound wins decisively on every practical dimension right now: it's approved, available, covered by insurance, and has years of real-world safety data. For anyone who needs treatment today, tirzepatide is the right answer.
The more interesting question is what happens in 2027–2028 when retatrutide reaches the market. Patients who plateaued on tirzepatide, patients with fatty liver disease, and patients who need maximum weight loss will have a compelling reason to switch or start with retatrutide. The two drugs will coexist and serve different patients — exactly as Ozempic and Mounjaro do today.